A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 402 participants.

Also called NCT01175811

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 402 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01175811
Other papers using this trial's data
  • Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial The lancet. Diabetes & endocrinology, 2015-04 DOI, PubMed 25754414

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China, South Korea, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01175811. Randomized; no masking; primary purpose treatment. Start 2011-02 (registry gives no type); primary completion 2012-11 (actual). Results posted on 2013-12-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Insulin Lispro Premix
Intervention (Drug)
Insulin Glargine
Intervention (Drug)
Insulin Lispro
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01175811
Content hash
075ab4f44e2686a4fa3904a82a8793a42ebf3245f35d54a5c5981f5c539496a9